FGFR2/3-Altered Intrahepatic Cholangiocarcinoma: A Distinct Clinicopathologic and Molecular Subtype Associated with Improved Disease-Specific Survival.

Wen-Yu Hsiao¹, Kartik Angara², Haider A Mejbel³

¹Department of Pathology, Gastrointestinal and Liver Pathology, Emory University School of Medicine, Atlanta, Georgia.

²Caris Life Sciences, Irving, Texas.

³Department of Pathology, Gastrointestinal and Liver Pathology, Emory University School of Medicine, Atlanta, Georgia; Department of Pathology, Molecular Genetics Pathology, Emory University School of Medicine, Atlanta, Georgia; Emory Winship Cancer Institute, Emory University, Atlanta, Georgia. Electronic address: haider.a.mejbel@emory.edu.

PubMed DOI

Abstract

Intrahepatic cholangiocarcinoma (iCCA) is an aggressive neoplasm with a poor prognosis. Fibroblast Growth Factor Receptor (FGFR) has emerged as a therapeutic target; however, the clinicopathologic, molecular, and prognostic features of FGFR-altered iCCAs remain incompletely defined. Thus, a 5-year retrospective study of genomically profiled iCCAs using dual whole-exome and whole-transcriptome sequ…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.